![Close-up of a patient 's hands filling out the SAGE test](/-/media/images/wexnermedical/pages/ways-to-give/ags-impact/alzheimers/sage_940x670.jpg?la=en&hash=866E1041352E936E779AB5B6D385E9AF)
Improving Disease Detection
Alzheimer’s is more treatable the earlier it’s detected, making the Self-Administered Gerocognitive Exam (SAGE) instrumental. The SAGE, which was developed by Douglas Scharre, MD, here at Ohio State, is now being used by physicians worldwide.
![Icon of a test sheet and pencil, white on purple background](/-/media/images/wexnermedical/pages/ways-to-give/ags-impact/alzheimers/alzheimers-icons_test-940x500.jpg?la=en&hash=279BD10CA89C8ECE4F467CA4895B2D7E)
Did you know...
The SAGE has identified patients 6 months earlier than other testing methods?
![Older patient with younger caregiver consulting with a doctor](/-/media/images/wexnermedical/pages/ways-to-give/ags-impact/alzheimers/alzheimers-940x670.jpg?la=en&hash=70FDB616716E7EB00CB409E95D93B60E)
Slowing Early Alzheimer’s
Early Alzheimer’s is characterized by the appearance of specific toxic protein deposits in the brain. We are conducting the VIVA-MIND Phase 2A clinical trial of an oral drug that could be critical to slowing — and even stopping — disease progression.![Icon of a calendar, white on a purple background](/-/media/images/wexnermedical/pages/ways-to-give/ags-impact/alzheimers/alzheimers-icons_calendar-940x500.jpg?la=en&hash=3EB835707B5D7D87A7C071F0744A706E)
Did you know...
Alzheimer’s begins 20 or more years before symptoms develop?
![Dr. Bankiewicz examining a vial in his lab](/-/media/images/wexnermedical/pages/ways-to-give/ags-impact/alzheimers/bankiewicz-940x670.jpg?la=en&hash=F47FB273F81A51896D7F00F8EB02938A)
Gene Therapy’s Promise
Gene therapy is designed to correct mutations in a person’s DNA. At Ohio State’s Gene Therapy Institute, we are pioneering research of the AAV2-BDNF, a study drug administered directly to the brain via surgery. A first-in-human clinical trial is now underway that could hold promise for future Alzheimer’s treatment.![Icon of a doctor and patient, white on a purple background](/-/media/images/wexnermedical/pages/ways-to-give/ags-impact/alzheimers/alzheimers-icons_doc-patient-500.jpg?la=en&hash=D0093E63A5B8E2484606DD9F48167E98)
Did you know...
Ohio State has conducted 200 dementia-related clinical trials over 20 years?
How you can help
Donate Online
Donate by Mail
The Wexner Medical Center Development Officec/o The OSU Foundation
PO Box 710811
Columbus, OH 43271-0811